Drug Discovery

An interview with Ken Gruber of Endevica Bio on his work producing a treatment for cachexia, a wasting condition common in late-stage cancer.

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

To optimize drug development, the opinions of all stakeholders – including patients – must be heard.

Two members of the Drugs for Neglected Diseases initiative lay out how they improved access to Hep C treatment in Southeast Asia and beyond.

Exploring the potential of vaccines for treatment equity.

How can the NLRP3 inflammasome can be exploited to slow the decline associated with Alzheimer's disease?

A drug development journey with origins in the 1950s has finally reached its successful conclusion: a new treatment for lupus.

Antibody drug conjugates are starting to transform cancer treatments, so let’s maintain the momentum.

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

Setting its sights on self-amplifying RNA, AstraZeneca has signed a deal with Imperial College London spinoff VaxEquity.